Novavax Nuvaxovid COVID-19 Vaccine Receives Expanded Authorization in Canada as a Booster in Adults

Novavax Inc. today announced that Health Canada has granted expanded authorization for Nuvaxovid™ (COVID-19 Vaccine (Recombinant protein, Adjuvanted)) (NVX-CoV2373) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a homologous booster in adults aged 18 and older. 'Canadians now have access to our protein-based Nuvaxovid COVID-19 vaccine as an adult booster,' said Stanley C. Erck, President and Chief Executive Officer, Novavax. 'With the winter months upon us, it's important to have options for vaccination to help protect against COVID-19.'